Department of Paediatrics, Faculty of Medicine, University of Kelaniya, Sri Lanka.
Colombo North Teaching Hospital, Ragama, Sri Lanka.
Pediatr Blood Cancer. 2019 May;66(5):e27643. doi: 10.1002/pbc.27643. Epub 2019 Jan 29.
Regular blood transfusion therapy still remains the cornerstone in the management of β-thalassemia. Although recommendations are clear for patients with β-thalassemia major, uniform transfusion guidelines are lacking for patients with hemoglobin E β-thalassemia. In this study, we aim to describe the adequacy, trends, and determinants of blood transfusion therapy in a large cohort of pediatric patients with β-thalassemia major and hemoglobin E β-thalassemia.
METHODS/PROCEDURE: This cross-sectional study was performed among all regularly transfused patents with β-thalassemia aged 2 to 18 years attending three large thalassemia centers in Sri Lanka. Data were collected using an interviewer-administered questionnaire, perusal of clinical records, and physical examination of patients by trained doctors.
A total of 328 patients (male 47%) were recruited; 83% had β-thalassemia major, whereas 16% had hemoglobin E β-thalassemia. Sixty-one percent of patients had low pretransfusion hemoglobin levels (< 9.0 g/dL) despite receiving high transfusion volumes (> 200 mL/kg/year) by a majority (56%). Median pretransfusion hemoglobin was significantly lower in patients with hemoglobin E β-thalassemia compared with β-thalassemia major (P < 0.001); however, there was no difference in requirement for high transfusion volumes over 200 mL/kg/year in both groups (P = 0.14). Hepatomegaly and splenomegaly were more common in hemoglobin E β-thalassemia and were associated with lower pretransfusion hemoglobin. Transfusion requirements were higher among patients with hepatitis C and in those who are underweight.
Over 60% of regularly transfused patients with β-thalassemia have low pretransfusion hemoglobin levels despite receiving large transfusion volumes. Patients with hemoglobin E β-thalassemia are undertransfused and specific recommendations should be developed to guide transfusions in these patients.
定期输血治疗仍然是β-地中海贫血管理的基石。虽然对重型β-地中海贫血患者有明确的建议,但缺乏血红蛋白 Eβ-地中海贫血患者的统一输血指南。在这项研究中,我们旨在描述大量重型β-地中海贫血和血红蛋白 Eβ-地中海贫血患儿接受输血治疗的充足性、趋势和决定因素。
方法/过程:这项横断面研究在斯里兰卡三个大型地中海贫血中心接受定期输血的所有 2 至 18 岁β-地中海贫血患者中进行。使用访谈者管理的问卷、查阅临床记录和由经过培训的医生对患者进行体格检查收集数据。
共招募了 328 名患者(男性占 47%);83%患有重型β-地中海贫血,16%患有血红蛋白 Eβ-地中海贫血。尽管大多数患者(56%)接受的输血体积>200mL/kg/年,但仍有 61%的患者存在低输血前血红蛋白水平(<9.0g/dL)。血红蛋白 Eβ-地中海贫血患者的输血前血红蛋白中位数明显低于重型β-地中海贫血患者(P<0.001);然而,两组患者对超过 200mL/kg/年的高输血体积的需求无差异(P=0.14)。血红蛋白 Eβ-地中海贫血患者更常见肝肿大和脾肿大,且与低输血前血红蛋白相关。丙型肝炎患者和体重不足患者的输血需求更高。
尽管接受了大量输血,但超过 60%的定期接受输血的β-地中海贫血患者输血前血红蛋白水平较低。血红蛋白 Eβ-地中海贫血患者输血不足,应制定具体建议指导这些患者的输血。